Novartis Starts Investigation On China Bribery Allegations; SAIC Initiates Crackdown On Illegal Competition
This article was originally published in PharmAsia News
Executive Summary
A Novartis sales representative in China has gone on record about fees given to doctors in exchange for prescriptions of a Novartis cancer therapy. Meanwhile, China’s State Administration for Industry and Commerce (SAIC) has started a three-month long enforcement campaign with a focus on pharmaceutical marketing and medical service.